Search

Your search keyword '"Lassen A"' showing total 159 results
Start Over Author "Lassen A" Journal annals of oncology
159 results on '"Lassen A"'

3. 463P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up

Author

McDermott, R.S., primary, van Tilburg, C., additional, Lin, J.J., additional, Kummar, S., additional, Tan, D.S.W., additional, Albert, C.M., additional, Berlin, J.D., additional, Lassen, U.N., additional, Doz, F., additional, Geoerger, B., additional, Mascarenhas, L., additional, Federman, N., additional, Norenberg, R., additional, Dima, L., additional, Mussi, C., additional, De La Cuesta, E.A., additional, Laetsch, T., additional, Hong, D.S., additional, and Drilon, A.E., additional

Published
2022
Full Text
View/download PDF

4. 464P Intra-patient (Pt) comparison from larotrectinib (Laro) clinical trials in tropomyosin receptor kinase (TRK) fusion cancer: An expanded dataset

Author

Italiano, A., primary, Drilon, A.E., additional, Shen, L., additional, Hong, D.S., additional, van Tilburg, C., additional, Tan, D.S.W., additional, Lin, J.J., additional, Kummar, S., additional, Doz, F., additional, Geoerger, B., additional, Brose, M.S., additional, Briggs, A., additional, Lassen, U.N., additional, Vassal, G., additional, Keating, K.N., additional, Norenberg, R., additional, Dima, L., additional, Brega, N., additional, Laetsch, T., additional, and Garcia-Foncillas, J., additional

Published
2022
Full Text
View/download PDF

6. 1350P Bridging the platforms of adaptive clinical trials in oncology and accelerating clinical research in rare genomic aberrations

Author

van Waalwijk van Doorn-Khosrovani, S., primary, Zeverijn, L.J., additional, Geurts, B.S., additional, de Wit, G.F., additional, Spiekman, I.A.C., additional, Pisters, A., additional, Pasmooij, A.M.G., additional, Timmers, L., additional, Nygren, H.P., additional, Rohrberg, K.S., additional, Peltola, K., additional, Mustonen, M.V.J., additional, Lassen, U.N., additional, Helland, A., additional, Gelderblom, H., additional, Verheul, H.M.W., additional, Tasken, K., additional, and Voest, E.E., additional

Published
2022
Full Text
View/download PDF

9. 1550P Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence

Author

van Waalwijk van Doorn-Khosrovani, S.B., Huisman, A.H., Timmer, H.J.L., Verkerk, K., Verbeek, F., Fagereng, L., Helland, A., Ryll, B., Tasken, K., Jalkanen, K., Oliveira, J., Lassen, U.N., Blay, J-Y., Gelderblom, H., Reyners, A., Eskens, F.A., Smit, E.F., Voest, E.E., and Bloemendal, H.

Published
2024
Full Text
View/download PDF

11. 61P Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib

Author

Moreno, V., primary, Lin, J.J., additional, Tan, D.S.W., additional, Lassen, U.N., additional, Leyvraz, S., additional, Liu, Y., additional, Patel, J., additional, Rosen, L., additional, Solomon, B., additional, Rudolph, M., additional, Norenberg, R., additional, Schulz, A., additional, Fellous, M., additional, Brega, N., additional, Shen, L., additional, Kummar, S., additional, and Drilon, A., additional

Published
2022
Full Text
View/download PDF

15. 55P Potential benefits of extensive genomic analysis in patients with KRAS mutated solid tumors: Concurrent alterations and potential targets

Author

Jacobsen, I.C., primary, Spanggaard, I., additional, Hoejgaard, M., additional, Belcaid, L., additional, Qvortrup, C., additional, Yde, C.W., additional, Schmidt, A.Y., additional, Nielsen, F.C., additional, Willemoe, G.L., additional, Dam, M.S., additional, Lassen, U., additional, and Rohrberg, K.S., additional

Published
2022
Full Text
View/download PDF

18. 534P Larotrectinib in non-CNS TRK fusion cancer patients: Outcomes by prior therapy and performance status

Author

Drilon, A., primary, Shen, L., additional, van Tilburg, C.M., additional, Tan, D.S.W., additional, Kummar, S., additional, Lin, J.J., additional, Doz, F., additional, McDermott, R., additional, Albert, C.M., additional, Berlin, J., additional, Bielack, S., additional, Lassen, U.N., additional, Tahara, M., additional, Norenberg, R., additional, Fellous, M., additional, Nogai, H., additional, Xu, R., additional, Laetsch, T.W., additional, and Hong, D.S., additional

Published
2021
Full Text
View/download PDF

19. 1711P The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine

Author

Gelderblom, H., Edsjö, A., Russnes, H.E.G., Lassen, U.N., Helland, A., Hallersjö Hult, E., Ryll, B., Lugowska, I., Blay, J-Y., Falk, R.S., van Waalwijk van Doorn-Khosrovani, S., Steen Carlsson, K., Peltola, K., Stenzinger, A., Vrdoljak, E., Oliveira, J., Haj Mohammad, S.F., Verheul, H.M.W., Voest, E.E., and Tasken, K.

Published
2023
Full Text
View/download PDF

24. 534P Larotrectinib in non-CNS TRK fusion cancer patients: Outcomes by prior therapy and performance status

Author

Catherine M. Albert, Francois P. Doz, Shivaani Kummar, D.S.W. Tan, Theodore W. Laetsch, Hendrik Nogai, Raymond S. McDermott, C.M. van Tilburg, A. Drilon, Stefan S. Bielack, Jordan Berlin, Jessica J. Lin, Makoto Tahara, Ulrik Lassen, David S. Hong, Ricarda Norenberg, R. Xu, Liang Shen, and Marc Mardoche Fellous

Subjects
Oncology, medicine.medical_specialty, Prior Therapy, Performance status, business.industry, Trk receptor, Internal medicine, Medicine, Cancer, Hematology, business, medicine.disease
Published
2021
Full Text
View/download PDF

25. 535P Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer

Author

Makoto Tahara, J. Lin, Serge Leyvraz, A. Drilon, S. Kummar, Jordan Berlin, Liang Shen, R. Norenberg, Laura Dima, David S. Hong, N. Brega, Ulrik Lassen, Raymond S. McDermott, Marcia S. Brose, D.S.W. Tan, and Jyoti D. Patel

Subjects
Oncology, Adult patients, business.industry, Kinase, Trk receptor, Cancer research, Medicine, Cancer, Hematology, business, medicine.disease, Receptor, Tropomyosin
Published
2021
Full Text
View/download PDF

27. First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

Author

Ute Ohnmacht, C. Le Tourneau, Gerard J. Oakley, Christophe Massard, Analia Azaro, Jordi Rodon, Debashis Sarker, Karim A. Benhadji, Bharvin K. R. Patel, Ulrik Lassen, Claire Smith, Eunice Yuen, and Jean-Charles Soria

Subjects
Adult, Male, 0301 basic medicine, Adolescent, Maximum Tolerated Dose, Colorectal cancer, medicine.medical_treatment, Notch signaling pathway, Administration, Oral, Antineoplastic Agents, colorectal cancer, Signal transduction inhibitor, Young Adult, 03 medical and health sciences, metastatic cancer, 0302 clinical medicine, Breast cancer, Neoplasms, medicine, Humans, Response Evaluation Criteria in Solid Tumors, Aged, LY3039478, Chemotherapy, Receptors, Notch, business.industry, Hematology, Benzazepines, Middle Aged, medicine.disease, Notch inhibition, 030104 developmental biology, Oncology, Notch proteins, Tolerability, Î 3-secretase inhibitors, 030220 oncology & carcinogenesis, Cancer research, Female, Amyloid Precursor Protein Secretases, business
Abstract

Background Deregulated Notch signaling due to mutation or overexpression of ligands and/or receptors is implicated in various human malignancies. γ-Secretase inhibitors inhibit Notch signaling by preventing cleavage of transmembrane domain of Notch protein. LY3039478 is a novel, potent Notch inhibitor decreases Notch signaling and its downstream biologic effects. In this first-in-human study, we report the safety, pharmacokinetic (PK) profile, pharmacodynamic effects, and antitumor activity of LY3039478 in patients with advanced or metastatic cancer. Methods This phase I, open-label, multicenter, nonrandomized, and dose-escalation phase study determined and confirmed the recommended phase II dose of LY3039478 (oral dose: 2.5–100 mg, thrice weekly (TIW) on a 28-day cycle). The primary objectives are to determine (part A) and confirm (part B) a recommended phase II dose that may be safely administered to patients with advanced or metastatic cancer, and secondary objectives include evaluation of safety, tolerability, PK parameters, and preliminary antitumor activity of LY3039478. Results A total of 110 patients were treated with LY3039478 monotherapy between 31 October 2012 and 15 July 2016. Dose-limiting toxicities were thrombocytopenia, colitis, and nausea. Most adverse events were gastrointestinal. The recommended phase II dose was 50 mg TIW, because of its better tolerability compared with 75 mg. The PKs of LY3039478 appeared dose proportional. Pharmacodynamic data indicate an ∼80% inhibition of plasma Aβ, and >50% inhibition of Notch-regulated genes hairy and enhancer of split-1, cyclin D1, and Notch-regulated ankyrin repeat at 45–100-mg dose. Clinical activity (tumor necrosis, metabolic response, or tumor shrinkage) was observed in patients with breast cancer, leiomyosarcoma, and adenoid cystic carcinoma. Conclusion Potent inhibition of Notch signaling by LY3039478 was well tolerated at doses associated with target engagement, and demonstrated evidence of clinical activity in heavily pretreated patients. Further investigation with LY3039478 as monotherapy and in combination with targeted agent or chemotherapy is ongoing. Clinicaltrials.gov ID NCT01695005.

Published
2018
Full Text
View/download PDF

29. 604TiP ON-TRK: A non-interventional study of larotrectinib in patients with TRK fusion cancer

Author

Leyvraz, S., primary, Yang, J.C-H., additional, Casali, P.G., additional, Castro, G., additional, Kim, E.S., additional, Lassen, U.N., additional, Lopez-Rios, F., additional, Penault-Llorca, F., additional, Pappo, A., additional, Rudzinski, E.R., additional, Tabatabai, G., additional, Vassal, G., additional, Reeves, J.A., additional, Nogai, H., additional, Fellous, M., additional, Drilon, A., additional, Brose, M.S., additional, and Trent, J., additional

Published
2020
Full Text
View/download PDF

32. 1955P Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer

Author

McDermott, R., primary, van Tilburg, C.M., additional, Farago, A.F., additional, Kummar, S., additional, Tan, D.S.W., additional, Albert, C.M., additional, Berlin, J., additional, Lassen, U.N., additional, Doz, F., additional, Geoerger, B., additional, Mascarenhas, L., additional, Federman, N., additional, Reeves, J.A., additional, Dima, L., additional, Brega, N., additional, De La Cuesta, E., additional, Laetsch, T.W., additional, Hong, D.S., additional, and Drilon, A., additional

Published
2020
Full Text
View/download PDF

33. 542P Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients

Author

Italiano, A., primary, Hong, D.S., additional, Briggs, A., additional, Garcia-Foncillas, J., additional, Lassen, U.N., additional, Vassal, G., additional, Kummar, S., additional, van Tilburg, C.M., additional, Keating, K., additional, Reeves, J.A., additional, Fellous, M., additional, Nogai, H., additional, Laetsch, T.W., additional, and Drilon, A., additional

Published
2020
Full Text
View/download PDF

34. 104P Matching-adjusted indirect comparison for treatment of NTRK fusion cancer with larotrectinib versus entrectinib

Author

Antoine Italiano, M. Fillbrunn, Jesús García-Foncillas, Karen Keating, Ulrik Lassen, R. Ayyagari, Carsten Bokemeyer, Marisca Marian, Wei Gao, Noman Paracha, and Marc Fellous

Subjects
Oncology, medicine.medical_specialty, Matching (statistics), business.industry, Internal medicine, Medicine, Cancer, Entrectinib, Hematology, business, medicine.disease, Indirect comparison
Published
2021
Full Text
View/download PDF

35. 542P Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients

Author

David S. Hong, A. Drilon, John A. Reeves, Ulrik Lassen, Hendrik Nogai, Marc Mardoche Fellous, Theodore W. Laetsch, Andrew Briggs, C.M. van Tilburg, Gilles Vassal, Antoine Italiano, Karen Keating, Jesús García-Foncillas, and Shivaani Kummar

Subjects
Oncology, medicine.medical_specialty, business.industry, Trk receptor, Internal medicine, Modulation index, medicine, Cancer, Hematology, business, medicine.disease
Published
2020
Full Text
View/download PDF

36. 1955P Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer

Author

D.S.W. Tan, Leo Mascarenhas, A. Drilon, Theodore W. Laetsch, Ulrik Lassen, Jordan Berlin, N. Brega, Anna F. Farago, C.M. van Tilburg, Catherine M. Albert, E. De La Cuesta, David S. Hong, Raymond S. McDermott, Birgit Geoerger, L. Dima, John A. Reeves, Noah Federman, Shivaani Kummar, and Francois P. Doz

Subjects
Oncology, medicine.medical_specialty, business.industry, Trk receptor, Internal medicine, medicine, Cancer, Hematology, medicine.disease, business
Published
2020
Full Text
View/download PDF

38. 591P Distress and perceived information among patients in phase I trials and their relatives: A prospective study

Author

Anne Katrine Duun-Henriksen, Christoffer Johansen, Beverley Lim Høeg, Iben Spanggaard, Katrine Toubro Gad, Morten Mau-Sørensen, Kristoffer Staal Rohrberg, A. von Heymann, Susanne Oksbjerg Dalton, Ulrik Lassen, and P.B. Envold

Subjects
Distress, medicine.medical_specialty, Oncology, business.industry, Emergency medicine, medicine, Phase i trials, Hematology, Prospective cohort study, business
Published
2020
Full Text
View/download PDF

39. 1289P Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer

Author

Ben Solomon, John A. Reeves, Jyoti D. Patel, Anna F. Farago, N. Brega, Victor Moreno, Lee S. Rosen, D.S.W. Tan, A. Drilon, Ulrik Lassen, Shivaani Kummar, Serge Leyvraz, and L. Dima

Subjects
Oncology, Kinase, business.industry, Trk receptor, Cancer research, Medicine, In patient, Hematology, Receptor, business, Lung cancer, medicine.disease, Tropomyosin
Published
2020
Full Text
View/download PDF

40. 604TiP ON-TRK: A non-interventional study of larotrectinib in patients with TRK fusion cancer

Author

J.C-H. Yang, Paolo G. Casali, John A. Reeves, A. Drilon, G. Castro, Ulrik Lassen, Marc Mardoche Fellous, Alberto S. Pappo, Erin R. Rudzinski, Frédérique Penault-Llorca, Gilles Vassal, Hendrik Nogai, Jonathan C. Trent, F. Lopez-Rios, Serge Leyvraz, Ghazaleh Tabatabai, Edward S. Kim, and Marcia S. Brose

Subjects
Oncology, medicine.medical_specialty, business.industry, Cancer, Hematology, Tropomyosin receptor kinase A, medicine.disease, Internal medicine, Trk receptor, Non interventional, Medicine, In patient, business
Published
2020
Full Text
View/download PDF

41. Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer

Author

Catherine M. Albert, Erin R. Rudzinski, T.W. Laetsch, Shivani Nanda, C.M. van Tilburg, David M. Hyman, Raymond S. McDermott, A. Drilon, Ulrik Lassen, Barrett H. Childs, Francois P. Doz, David S. Hong, Steven G. DuBois, Shivaani Kummar, Michael C. Cox, Daniel Shao-Weng Tan, Jordan Berlin, Anna F. Farago, Birgit Geoerger, and Leo Mascarenhas

Subjects
0301 basic medicine, medicine.medical_specialty, Disease status, business.industry, Constitutively active, Stock options, Hematology, Gene rearrangement, Salivary gland carcinoma, 03 medical and health sciences, Safety profile, 030104 developmental biology, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Family medicine, Visual accommodation, medicine, In patient, business
Abstract

Background Genomic rearrangements involving NTRK1/2/3 result in constitutively active TRK fusion proteins that are oncogenic drivers in multiple pediatric and adult cancers. Larotrectinib is a selective TRK inhibitor approved by the FDA in 2018 for the treatment of any TRK fusion cancer based on a primary analysis in 55 patients from 3 clinical trials [Drilon et al. NEJM 2018]. For the first time, we now report median duration of response (DOR) data in this primary cohort, as well as updated data in an expanded cohort of 159 total TRK fusion patients treated with larotrectinib, with 153 (55 primary + 98 supplemental) evaluable for efficacy. Methods Patients with TRK fusion cancer detected by local molecular profiling were treated with larotrectinib across 3 studies (NCT02122913, NCT02637687, and NCT02576431). Disease status was assessed by investigators using RECIST 1.1. Data cut-off was 19 February 2019. Results In the primary cohort of 55 patients with a median follow-up of 26 months, the median DOR in 44 patients with complete or partial responses was 35.2 months (95% CI 21.2–NE), with 17 progression events and 27 responses ongoing (range 1.6–44 months). The median PFS in the primary cohort was 25.8 months (95% CI 9.9–NE), with 27 patients having progressed. In the expanded combined dataset, the most common tumor types included soft tissue sarcoma (n = 36), infantile fibrosarcoma (n = 29), thyroid carcinoma (n = 26), salivary gland carcinoma (n = 21), and lung cancer (n = 12). The median age was 43 years, ranging from Conclusions These data confirm the marked tissue-agnostic efficacy and long durability of response in patients with TRK fusion cancer treated with larotrectinib. Larotrectinib continued to demonstrate a favorable long-term safety profile. Screening patients for NTRK gene fusions should be actively considered. Clinical trial identification NCT02122913, NCT02637687, NCT02576431. Editorial acknowledgement Editorial assistance was provided by Michael Sheldon, PhD, of Scion, London, UK, funded by Bayer. Legal entity responsible for the study Bayer. Funding Bayer. Disclosure D.M. Hyman: Advisory / Consultancy: Chugai Pharma, CytomX Therapeutics, Boehringer Ingelheim, AstraZeneca, Pfizer, Bayer Pharmaceuticals, Genentech / F. Hoffmann-La Roche; Research grant / Funding (self): Loxo Oncology, Bayer Pharmaceuticals, PUMA Biotechnology, AstraZeneca. C.M. van Tilburg: Advisory / Consultancy: Novartis, Bayer. D.S.W. Tan: Advisory / Consultancy: Novartis, Merck Loxo AstraZeneca Roche Pfizer; Travel / Accommodation / Expenses: Pfizer Boehringer Ingelheim Roche; Honoraria (self): BMS, Takeda, Novartis, Roche, Pfizer; Research grant / Funding (self): Novartis, GSK, AstraZeneca. A.F. Farago: Research grant / Funding (self): Bayer, Loxo Oncology; Advisory / Consultancy: Bayer, Loxo Oncology. T.W. Laetsch: Advisory / Consultancy: Novartis, Bayer, Loxo, Lill; Research grant / Funding (self): Pfizer Novartis Bayer Loxo Abbvie Amgen Atara Biotherapeutics BMS Lilly Epizyme GSK Janssen Jubilant Pharmaceuticals Novella Clinical, Servier. S. Kummar: Honoraria (self): Bayer; Advisory / Consultancy: Bayer; Travel / Accommodation / Expenses: Bayer. F. Doz: Research grant / Funding (institution): BMS, Celgene; Travel / Accommodation / Expenses: BMS; Advisory / Consultancy: Bayer, BMS, Celgene, Loxo Oncology, Servier. U.N. Lassen: Advisory / Consultancy: Bayer; Advisory / Consultancy: Pfizer. S.G. DuBois: Advisory / Consultancy: Loxo; Travel / Accommodation / Expenses: Loxo, Roche; Honoraria (self): Loxo; Research grant / Funding (self): Millennium, Merck, Novartis Roche Lilly Lilly Loxo BMS. R. McDermott: Travel / Accommodation / Expenses: Janssen-Cilag, Pfizer; Honoraria (self): Bayer, Sanofi, Janssen, Astellas, BMS, MSD, Pfizer, Novartis, Clovis; Research grant / Funding (self): Sanofi, Janssen, Bayer, Astellas. L. Mascarenhas: Research grant / Funding (institution): AstraZeneca, Eli Lilly. J.D. Berlin: Research grant / Funding (institution): PsiOxus, Bayer, EMD Serono, Symphogen, Roche/Genentech, Immunomedics, Novartis, Taiho, AbbVie (pharamcyclics), Boston Biomedical, FivePrime, Loxo, Incyte, Macrogenics; Honoraria (self): Nestle; Advisory / Consultancy: Rafeal, Seattle Genetics, EMD Serono, Bayer, eisai, Taiho, Armo,Gritstone, AstraZeneca, Celgene, Erytech. E.R. Rudzinski: Advisory / Consultancy: Bayer. M.C. Cox: Full / Part-time employment: Loxo Oncology. S. Nanda: Full / Part-time employment: Loxo Oncology. B.H. Childs: Full / Part-time employment: Bayer. A. Drilon: Advisory / Consultancy: Loxo Oncology/Bayer, Ignyta, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech/Roche, Takeda/Ariad/Millenium, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Bayer, Tyra; Research grant / Funding (self): Foundation Medicine; Licensing / Royalties: Wolters Kluwer; Honoraria (institution): Pfizer, Exelixis, GlaxoSmithKline, Teva, Taiho; Travel / Accommodation / Expenses: Merck; Advisory / Consultancy: MORE Health. D.S. Hong: Research grant / Funding (self): AbbVie, Adaptimmune, Amgen, AstraZeneca, Bayer, BMS, Daiichi-Sankyo, Eisai, Fate Therapeutics, Genentech, Genmab, Ignyta, Infinity, Kite, Kyowa, Lilly, LOXO, Merck, MedImmune, Mirati, MiRNA, Molecular Templates, Mologen, NCI-CTEP, Novartis, Pfizer, Seatt; Travel / Accommodation / Expenses: Loxo, MiRNA, ASCO, AACR, SITC, Genmab; Advisory / Consultancy: Alpha Insights, Axiom, Adaptimmune, Baxter, Bayer, Genentech, GLG, Group H, Guidepoint Global, Infinity, Janssen, Merrimack, Medscape, Numab, Pfizer, Seattle Genetics, Takeda, Trieza Therapeutics; Shareholder / Stockholder / Stock options: Molecular Match, OncoResponse, Presagia Inc. All other authors have declared no conflicts of interest.

Published
2019
Full Text
View/download PDF

42. Activity of larotrectinib in TRK fusion lung cancer

Author

Lee S. Rosen, Shivaani Kummar, N C Ku, A. Drilon, Jyoti D. Patel, Anna F. Farago, Moreno, Michael C. Cox, Barrett H. Childs, Shivani Nanda, and U. Lassen

Subjects
Oncology, business.industry, Trk receptor, Cancer research, medicine, Hematology, Lung cancer, medicine.disease, business
Published
2019
Full Text
View/download PDF

43. Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer

Author

Hyman, D., primary, Tan, D.S.W., additional, van Tilburg, C., additional, Albert, C., additional, Geoerger, B., additional, Farago, A., additional, Laetsch, T., additional, Kummar, S., additional, Doz, F., additional, Lassen, U., additional, Dubois, S., additional, McDermott, R., additional, Mascarenhas, L., additional, Berlin, J., additional, Rudzinski, E., additional, Nanda, S., additional, Childs, B., additional, Drilon, A., additional, and Hong, D.S., additional

Published
2019
Full Text
View/download PDF

44. Activity of larotrectinib in TRK fusion lung cancer

Author

Drilon, A., primary, Kummar, S., additional, Moreno, V., additional, Patel, J., additional, Lassen, U., additional, Rosen, L., additional, Childs, B.H., additional, Nanda, S., additional, Cox, M.C., additional, Ku, N.C., additional, and Farago, A.F., additional

Published
2019
Full Text
View/download PDF

46. Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

Author

Tan, D.S.W., primary, Lassen, U.N., additional, Albert, C.M., additional, Kummar, S., additional, van Tilburg, C., additional, Dubois, S.G., additional, Geoerger, B., additional, Mascarenhas, L., additional, Federman, N., additional, Basu-Mallick, A., additional, Doz, F., additional, Berlin, J.D., additional, Oh, D.-Y., additional, Bielack, S., additional, McDermott, R., additional, Cruickshank, S., additional, Ku, N.C., additional, Cox, M.C., additional, Drilon, A., additional, and Hong, D.S., additional

Published
2018
Full Text
View/download PDF

47. A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting interleukin-1 receptor accessory protein (IL1RAP), in patients with solid tumors

Author

Awada, A., primary, Eskens, F.A.L.M., additional, Robbrecht, D.G., additional, Lassen, U.N., additional, Sorensen, M., additional, Schellens, J.H.M., additional, de Groot, J.S., additional, Jungels, C., additional, Aftimos, P.G., additional, Fretland, S.O., additional, Thorsson, L., additional, and Guren, T.K., additional

Published
2018
Full Text
View/download PDF

48. A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort

Author

Concin, N., primary, Vergote, I.B., additional, Lassen, U.N., additional, Drew, Y., additional, Machiels, J.-P., additional, Arkenau, H.-T., additional, Forster, M.D., additional, Jones, R., additional, Johnson, M.L., additional, Slomovitz, B.M., additional, Spicer, J., additional, Cornez, N., additional, Gennigens, C., additional, Coleman, R.L., additional, Windfeld, K., additional, Ghatta, S., additional, Rangwala, R.A., additional, and Hong, D.S., additional

Published
2018
Full Text
View/download PDF

49. Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)

Author

Melero, I., primary, Castanon Alvarez, E., additional, Mau-Sorensen, M., additional, Lassen, U.N., additional, Lolkema, M.P., additional, Robbrecht, D.G., additional, Gomez-Roca, C.A., additional, Martin-Liberal, J., additional, Tabernero, J., additional, Ros, W., additional, Ahmed, S., additional, Isambert, N., additional, Piper Lepoutre, H., additional, Boetsch, C., additional, Charo, J., additional, Evers, S., additional, Teichgräber, V., additional, and Schellens, J.H.M., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results